TIDMCOG
RNS Number : 8855B
Cambridge Cognition Holdings PLC
22 June 2016
22 June 2016
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Distribution agreement with MANUS Neurodynamica
The neuroscience technology company Cambridge Cognition Holdings
PLC (Cambridge, UK - LSE: COG), which develops and markets products
and technologies for near-patient cognitive assessment, has entered
into a distribution agreement with UK healthcare technology company
MANUS Neurodynamica Limited.
The agreement provides Cambridge Cognition with sole rights to
market the MANUS Parkinson's Pen, a sensor pen for diagnosis and
monitoring of neuromotor impairments, in academic research,
pharmaceutical clinical trials and occupational health markets. The
CE Class I medical device uses non-invasive, patented technology to
record and analyse limb and hand motion to assess underlying
neuromotor processes, particularly for patients with Parkinson's
disease.
An estimated seven to 10 million people worldwide are living
with Parkinson's disease, which is predicted to more than double by
the year 2040.(1) The combined direct and indirect cost of
Parkinson's is estimated to be nearly $25 billion per year in the
United States alone.(2)
Early diagnosis and timely access to specialist care for
patients is essential. However, current diagnostic methods for
Parkinson's disease are based on a clinician's subjective
interpretation or neuroimaging techniques, which are expensive,
invasive and require skilled operators. The Parkinson's pen will
provide an easy to use, non-invasive alternative.
Following completion of final product enhancements, Cambridge
Cognition expects to begin marketing the product initially for use
in academic research through its existing global sales channels in
Q4 2016. The product will subsequently be marketed for use by
healthcare professionals to improve the certainty of differential
diagnosis; in pre-symptomatic screening to identify and triage
patients at risk and in monitoring disease severity in Parkinson's
patients by GPs and specialists in Europe and the US.
Use of the MANUS Parkinson's pen will provide a more accurate
low-cost measure in clinical research and provide a direct cost
reduction by assisting with a timely, accurate disease diagnosis to
enable early treatment and avoid patient deterioration to the stage
where intervention costs increase.
Dr Rutger Zietsma, Managing Director of MANUS Neurodynamica:
"The pen is a unique product linking over ten years of research
with sensor systems and development of data analysis methods for
Parkinson's disease. Cambridge Cognition is the perfect partner for
MANUS products with their reputation for providing high-end,
innovative and clinically validated neuroscientific products and
well-established commercial partnerships with leading academic
institutions and the biopharmaceutical industry globally. We are
very excited about this collaboration and the planned exploitation
of our Parkinson's pen product as well as the possibilities of
future synergistic product development."
Dr. Steven Powell, Chief Executive Officer, Cambridge Cognition:
"Research and development in Parkinson's disease is a key field for
Cambridge Cognition and a hugely important area of research. The
addition of the MANUS Parkinson's pen to our neurotechnology
portfolio enables us to further leverage our investments in
commercial channels and allows us to combine world leading
cognitive assessments with cutting-edge physical measures as we
continue to advance the understanding, diagnosis and treatment of
neurological disorders worldwide."
(1) Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V. and
Jain, A. (2013), The current and projected economic
burden of Parkinson's disease in the United States. Mov.
Disord., 28: 311-318.
(2) Parkinson's Disease Foundation. (2016), Statistics on
Parkinson's. www.pdf.org/en/parkinson_statistics.
Enquiries
Cambridge Cognition Holdings plc www.cambridgecognition.com
Steven Powell, Chief Executive Tel: 01223 810
Officer 700
Noah Konig, Director of Product press@camcog.com
Marketing and Communications
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane (Corporate Broking)
Hybridan LLP (Joint Broker) Tel: 020 3764
2341
Claire Noyce (Corporate Broking)
Manus Neurodynamica Ltd Tel: 07870100160
Rutger Zietsma, Managing director
Exordium Consulting (Advisor to Manus Neurodynamica) Tel: 07738733663
Keith Redpath
About Cambridge Cognition
Cambridge Cognition is a leading neuroscience technology company
delivering near-patient assessment solutions to improve the
understanding, diagnosis and treatment of neurological and
psychiatric disorders.
For over 30 years the Company's innovative CANTAB(R) technology
has advanced the assessment of cognition in global scientific
research; clinical trials; and clinical practice, accelerating the
development of safe and effective treatments, improving patient
outcomes and to helping assess, monitor and manage cognitive health
throughout life.
Customers and partners include the world's leading biotechnology
and pharmaceutical companies; renowned academic institutions; and
public-private healthcare providers.
For further information, visit www.cambridgecognition.com
About MANUS Neurodynamica
Experts in developing, patenting and marketing medical
technologies, MANUS Neurodynamica is radically innovating health
care management in the emerging field of diagnostics for neuromotor
impairments.
The principal product, a sensory pen for diagnosis and
monitoring of neuromotor impairments, is a non-invasive, patented
technology that records and analyses limb and hand motion to assess
the underlying neuromotor processes, particularly for patients with
Parkinson's disease.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRBRGDLIDDBGLB
(END) Dow Jones Newswires
June 22, 2016 02:00 ET (06:00 GMT)